Pompe disease in infants and children. [J Pediatr. 2004] - PubMed

loading

First treatment for Pompe disease. [FDA Consum. 2006]
First treatment for Pompe disease.
[No authors listed]FDA Consum. 2006 Jul-Aug; 40(4):3.
Prognostic factors for late-onset Pompe disease with enzyme replacement therapy: The two sides of low BMI. [Mol Genet Metab. 2010]
Prognostic factors for late-onset Pompe disease with enzyme replacement therapy: The two sides of low BMI.
Ravaglia S, Carlucci A, Danesino C. Mol Genet Metab. 2010 Aug; 100(4):388. Epub 2010 Apr 20.
Alglucosidase alfa: new drug. Pompe disease: a short-term benefit. [Prescrire Int. 2007]
Alglucosidase alfa: new drug. Pompe disease: a short-term benefit.
[No authors listed]Prescrire Int. 2007 Dec; 16(92):240-1.
Review Pompe disease: current state of treatment modalities and animal models. [Mol Genet Metab. 2007]
Review Pompe disease: current state of treatment modalities and animal models.
Geel TM, McLaughlin PM, de Leij LF, Ruiters MH, Niezen-Koning KE. Mol Genet Metab. 2007 Dec; 92(4):299-307. Epub 2007 Sep 7.
Review Pompe disease (glycogen storage disease type II): clinical features and enzyme replacement therapy. [Acta Neurol Belg. 2006]
Review Pompe disease (glycogen storage disease type II): clinical features and enzyme replacement therapy.
van der Beek NA, Hagemans ML, van der Ploeg AT, Reuser AJ, van Doorn PA. Acta Neurol Belg. 2006 Jun; 106(2):82-6.

Hypertransaminasemia and fatal lung disease: a case report. [Ital J Pediatr. 2013]
Hypertransaminasemia and fatal lung disease: a case report.
Santamaria F, De Stefano S, Montella S, Maglione M, Della Casa R, Acampora E, Pignata C, Salerno M, Parenti G. Ital J Pediatr. 2013 Feb 7; 39:9. Epub 2013 Feb 7.
The pharmacological chaperone AT2220 increases recombinant human acid α-glucosidase uptake and glycogen reduction in a mouse model of Pompe disease. [PLoS One. 2012]
The pharmacological chaperone AT2220 increases recombinant human acid α-glucosidase uptake and glycogen reduction in a mouse model of Pompe disease.
Khanna R, Flanagan JJ, Feng J, Soska R, Frascella M, Pellegrino LJ, Lun Y, Guillen D, Lockhart DJ, Valenzano KJ. PLoS One. 2012; 7(7):e40776. Epub 2012 Jul 18.
Review Consensus treatment recommendations for late-onset Pompe disease. [Muscle Nerve. 2012]
Review Consensus treatment recommendations for late-onset Pompe disease.
Cupler EJ, Berger KI, Leshner RT, Wolfe GI, Han JJ, Barohn RJ, Kissel JT, AANEM Consensus Committee on Late-onset Pompe Disease. Muscle Nerve. 2012 Mar; 45(3):319-33. Epub 2011 Dec 15.

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Pompe disease in infants and children.
Pompe disease in infants and children.
J Pediatr. 2004 May ;144(5 Suppl):S35-43.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

PubMed